Open AccessHepatitis B virus reactivation with a rituximab-containing regimen
Author(s) -
Yutaka Tsutsumi,
Yoshiya Yamamoto,
Itó S,
Hiroyuki Ohigashi,
Souichi Shiratori,
Hirohito Naruse,
Takanori Teshima
Publication year - 2015
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v7.i21.2344
Subject(s) - medicine , rituximab , hepatitis b virus , immunology , regimen , hepatitis b , disease , lymphoma , intensive care medicine , virus
Rituximab is currently used not only in the treatment of B-cell lymphoma but also for various other diseases, including autoimmune diseases, post-transplant graft vs host disease, and rejection following kidney transplants. Due to rituximab's widespread use, great progress has been made regarding research into complications that arise from its use, one of the most serious being the reactivation of hepatitis B virus (HBV), and efforts continue to establish guidelines for preventive treatment against this occurrence. This report discusses preventive measures against rituximab-induced HBV reactivation and future objectives.